Autopsy report · NCT01910441
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Cause of deathOther
“The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.”
Life of this trial
- Ran for about 1 year 2 months before it stopped.
- 95 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Vildagliptin; Glimepiride; Metformin
- Participants
- 95
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.